X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Unichem Lab with Dishman Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

UNICHEM LAB vs DISHMAN PHARMA - Comparison Results

DISHMAN PHARMA 
   Change

Dishman Pharmaceuticals is involved in the manufacture of APIs (active pharmaceutical ingredients), intermediates, quaternary compounds and fine chemicals. Besides this, the company is a significant player in the CRAMS (Contract Research and Manufact... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    UNICHEM LAB DISHMAN PHARMA UNICHEM LAB/
DISHMAN PHARMA
 
P/E (TTM) x -64.7 25.1 - View Chart
P/BV x 0.7 3.3 21.6% View Chart
Dividend Yield % 2.3 0.7 351.7%  

Financials

 UNICHEM LAB   DISHMAN PHARMA
EQUITY SHARE DATA
    UNICHEM LAB
Mar-18
DISHMAN PHARMA
Mar-16
UNICHEM LAB/
DISHMAN PHARMA
5-Yr Chart
Click to enlarge
High Rs382374 102.0%   
Low Rs234129 181.6%   
Sales per share (Unadj.) Rs116.3197.8 58.8%  
Earnings per share (Unadj.) Rs-18.921.2 -89.2%  
Cash flow per share (Unadj.) Rs-11.734.7 -33.8%  
Dividends per share (Unadj.) Rs5.002.00 250.0%  
Dividend yield (eoy) %1.60.8 204.2%  
Book value per share (Unadj.) Rs381.0179.9 211.8%  
Shares outstanding (eoy) m70.3480.69 87.2%   
Bonus/Rights/Conversions BB--  
Price / Sales ratio x2.61.3 208.2%   
Avg P/E ratio x-16.311.9 -137.2%  
P/CF ratio (eoy) x-26.27.2 -362.0%  
Price / Book Value ratio x0.81.4 57.8%  
Dividend payout %-26.49.4 -280.2%   
Avg Mkt Cap Rs m21,66820,306 106.7%   
No. of employees `0002.30.8 275.0%   
Total wages/salary Rs m2,0065,355 37.5%   
Avg. sales/employee Rs Th3,587.819,252.7 18.6%   
Avg. wages/employee Rs Th880.06,459.5 13.6%   
Avg. net profit/employee Rs Th-583.72,064.1 -28.3%   
INCOME DATA
Net Sales Rs m8,18015,961 51.3%  
Other income Rs m610265 229.9%   
Total revenues Rs m8,79016,226 54.2%   
Gross profit Rs m-1,3204,103 -32.2%  
Depreciation Rs m5051,091 46.3%   
Interest Rs m80944 8.5%   
Profit before tax Rs m-1,2952,334 -55.5%   
Minority Interest Rs m00-   
Prior Period Items Rs m-21 -200.0%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m33624 5.4%   
Profit after tax Rs m-1,3311,711 -77.8%  
Gross profit margin %-16.125.7 -62.8%  
Effective tax rate %-2.626.7 -9.7%   
Net profit margin %-16.310.7 -151.8%  
BALANCE SHEET DATA
Current assets Rs m23,31811,018 211.6%   
Current liabilities Rs m4,6359,517 48.7%   
Net working cap to sales %228.49.4 2,428.7%  
Current ratio x5.01.2 434.5%  
Inventory Days Days122110 110.2%  
Debtors Days Days12135 348.7%  
Net fixed assets Rs m8,16316,304 50.1%   
Share capital Rs m141161 87.2%   
"Free" reserves Rs m26,66012,907 206.6%   
Net worth Rs m26,80114,516 184.6%   
Long term debt Rs m34,189 0.1%   
Total assets Rs m31,89029,805 107.0%  
Interest coverage x-15.23.5 -437.1%   
Debt to equity ratio x00.3 0.0%  
Sales to assets ratio x0.30.5 47.9%   
Return on assets %-3.98.9 -44.0%  
Return on equity %-5.011.8 -42.1%  
Return on capital %-4.517.5 -25.9%  
Exports to sales %024.8 0.0%   
Imports to sales %03.7 0.0%   
Exports (fob) Rs mNA3,956 0.0%   
Imports (cif) Rs mNA596 0.0%   
Fx inflow Rs m4,3564,952 88.0%   
Fx outflow Rs m0697 0.0%   
Net fx Rs m4,3564,255 102.4%   
CASH FLOW
From Operations Rs m-1,1232,786 -40.3%  
From Investments Rs m16,487-1,529 -1,078.3%  
From Financial Activity Rs m-8,811-941 936.3%  
Net Cashflow Rs m6,552316 2,070.8%  

Share Holding

Indian Promoters % 50.1 61.4 81.6%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 15.1 3.7 408.1%  
FIIs % 3.0 12.7 23.6%  
ADR/GDR % 0.0 0.0 -  
Free float % 31.7 22.1 143.4%  
Shareholders   20,176 46,261 43.6%  
Pledged promoter(s) holding % 0.0 35.8 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare UNICHEM LAB With:   DR. DATSONS LABS  STRIDES SHASUN LTD  J.B.CHEMICALS  JUBILANT LIFE SCIENCES  DIVIS LABORATORIES  

Compare UNICHEM LAB With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Slumps Over 275 Points; Realty and Banking Stocks Witness Selling(Closing)

After trading on a volatile note throughout the day, share markets in India witnessed selling pressure during the closing hours and ended the day in red.

Related Views on News

UNICHEM LAB Announces Quarterly Results (1QFY19); Net Profit Down 1479.6% (Quarterly Result Update)

Aug 3, 2018 | Updated on Aug 3, 2018

For the quarter ended June 2018, UNICHEM LAB has posted a net profit of Rs 207 m (down 1479.6% YoY). Sales on the other hand came in at Rs 2 bn (down 35.9% YoY). Read on for a complete analysis of UNICHEM LAB's quarterly results.

UNICHEM LAB Announces Quarterly Results (4QFY18); Net Profit Down 91.1% (Quarterly Result Update)

Jun 14, 2018 | Updated on Jun 14, 2018

For the quarter ended March 2018, UNICHEM LAB has posted a net profit of Rs 28 m (down 91.1% YoY). Sales on the other hand came in at Rs 2 bn (down 40.4% YoY). Read on for a complete analysis of UNICHEM LAB's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

Is It the Right Time to Buy Pharma Stocks Now?(The 5 Minute Wrapup)

Sep 12, 2018

Is the pharma sector poised for a comeback? Is the worst over? I believe so.

Want Bigger Returns Than You Thought Possible? This is Where You Should Look(Profit Hunter)

Sep 12, 2018

Richa has discovered the single most profitable opportunity in the market - read on to discover more...

Investors Are Redeeming From Equity Mutual Funds Now. Should You?(Outside View)

Sep 12, 2018

PersonalFN elucidates if you should redeem from equity mutual fund now, and the approach to follow before you decide to sell mutual funds.

Are You Blindly Investing In Equities? Read This...(Outside View)

Sep 11, 2018

PersonalFN explains how blindly investing in equities can prove hazardous to your wealth and health.

Outperformance of Strong Established Brands in the Indian Stock market(Chart Of The Day)

Sep 14, 2018

Strong Well established Indian Brands have comfortably outperformed the index in the decade post the global financial crisis.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

UNICHEM LAB SHARE PRICE


Sep 21, 2018 03:37 PM

TRACK UNICHEM LAB

  • Track your investment in UNICHEM LAB with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

UNICHEM LAB - CADILA HEALTHCARE COMPARISON

COMPARE UNICHEM LAB WITH

MARKET STATS